AstraZeneca Inks R&D Deal With Ramaswamy's Roivant for Hush-Hush Indication Post author:Sam Post published:October 18, 2017 Post category:BioPharma Vivek Ramaswamy’s parent company, Roivant Sciences, inked a development deal with Astra. Source: BioSpace You Might Also Like Unilife Slashes Workforce and May Not Have Enough Cash to Survive Beyond This Week April 4, 2017 Active Biotech's Laquinimod Fails to Meet Primary Endpoint in Phase II Trial November 30, 2017 Why AbbVie Could Join the M&A Mania Soon January 30, 2018
